Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease

Trial Profile

Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2018

At a glance

  • Drugs CDNF (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Herantis Pharma
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Aug 2018 According to a Herantis Pharma media release, the trial had been expanded with two additional sites at the university hospitals in Helsinki and Lund in addition to the first site in Stockholm based on a favorable safety evaluation by the independent data safety monitoring board and their recommendation to continue the study as planned.
    • 13 Mar 2018 Last checked against European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top